Methergin (Methylergometrine Maleate)

Methergin is a uterotonic agent used in obstetric care to manage bleeding and promote uterine tone.

• Postpartum hemorrhage: provides rapid uterine contraction to reduce blood loss after childbirth.
• Post‑delivery uterine bleeding: helps control ongoing bleeding by sustaining uterine tone.
• Obstetric procedures: induces uterine contraction when required during surgical or medical obstetric interventions.

• Methylergometrine Maleate acts as a partial agonist at serotonin 5‑HT2 receptors and alpha‑adrenergic receptors in uterine smooth muscle. Stimulation of these receptors triggers sustained calcium influx, leading to prolonged contraction of the myometrium and reduction of uterine blood flow, thereby controlling hemorrhage.

Methergin may cause a range of adverse reactions, ranging from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Vomiting: occasional episodes after administration.
• Headache: transient cranial discomfort.
• Hypertension: temporary rise in blood pressure.
• Peripheral vasoconstriction: cold extremities or tingling.

Serious or Rare Side Effects

• Myocardial ischemia: chest pain or cardiac events.
• Pulmonary edema: difficulty breathing, fluid accumulation.
• Severe hypertension: markedly elevated blood pressure requiring intervention.
• Cerebral vasospasm: neurological symptoms such as visual disturbances.
• Allergic reaction: rash, itching, or anaphylaxis.

Methergin should be used with careful clinical assessment and monitoring.

• Contraindication: avoid in patients with hypertension or cardiovascular disease due to risk of severe blood pressure elevation.
• Monitoring: observe blood pressure and heart rate during and after administration.
• Caution in liver disease: impaired metabolism may increase drug exposure.
• Use in obstetric emergencies only: limit to situations where benefits outweigh risks.
• Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Methergin can interact with several drug classes, altering its safety profile.

Major Interactions (Avoid)

• MAO inhibitors: risk of hypertensive crisis.
• Sympathomimetic agents: additive vasoconstriction and hypertension.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs: may blunt intended uterine contraction.
• CYP450 inducers or inhibitors: may affect plasma levels of methylergometrine.
• Other ergot alkaloids: increased risk of vasospasm and ischemia.